<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191060</url>
  </required_header>
  <id_info>
    <org_study_id>09 110 01</org_study_id>
    <nct_id>NCT01191060</nct_id>
  </id_info>
  <brief_title>Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years</brief_title>
  <acronym>IFM/DFCI2009</acronym>
  <official_title>Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is to determine if, in the era of novel drugs, high dose therapy
      (HDT) is still necessary in the initial management of multiple myeloma in younger patients.
      HDT as compared to conventional dose treatment would be considered superior if it
      significantly prolongs Progression-free survival (by at least 9 months).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design Phase III, multicenter, randomized, open-label study designed to evaluate the
      clinical benefit from the drug combination RVD without immediate high-dose therapy (HDT)
      followed by lenalidomide maintenance (Arm A) versus RVD plus HDT and PBSCT followed by
      lenalidomide maintenance (Arm B).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 4 years</time_frame>
    <description>To compare progression-free survival (PFS) between the Arm A and Arm B up to 4 years or until progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rates</measure>
    <time_frame>up to 4 years</time_frame>
    <description>-Response rates (RR) between the two arms up to 4 years or until progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Time to progression (TTP) between the two arms up to 4 years or until progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity comparison</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Toxicity comparison between the two arms randomization up to 4 years or until progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic prognostic groups definition</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Genetic prognostic groups definition (evaluated by gene expression profiling-GEP) from randomization up to 4 years or until progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best treatment examination in each GEP-defined prognostic group.</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Best treatment examination in each GEP-defined prognostic group. from randomization up to 4 years or until progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>lenalidomide, bortezomib with ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent)
Autologous stem cell transplant:
Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lenalidomide, bortezomib without ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Bortezomib</intervention_name>
    <description>Lenalidomide/Bortézomib/Dexamethasone cycles:
Number of cycles: 8 cycles for arm A
Cycle length
Dosage:
Lenalidomide: 25 mg/day on days 1-14 of each cycle
Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle
Maintenance phase (12 months):
Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed</description>
    <arm_group_label>lenalidomide, bortezomib without ASCT</arm_group_label>
    <other_name>Lenalidomide (REVLIMID®)</other_name>
    <other_name>Bortezomib (VELCADE®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Bortezomib</intervention_name>
    <description>Lenalidomide Bortezomib Dexamethasone cycles:
Number of cycles: 5 cycles for arm B
Cycle length
Dosage:
Lenalidomide: 25 mg/day on days 1-14 of each cycle
Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle
Maintenance phase (12 months):
Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed</description>
    <arm_group_label>lenalidomide, bortezomib with ASCT</arm_group_label>
    <other_name>Lenalidomide (REVLIMID®)</other_name>
    <other_name>Bortézomib (VELCADE®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for registration :

        (with labs performed within 21 days of initiation of protocol therapy):

          -  Patients diagnosed with multiple myeloma based on International Myeloma Foundation
             2003 Diagnostic Criteria.

          -  Patients must have symptomatic myeloma with myeloma-related organ damage.

          -  Patients must have myeloma that is measurable by either serum or urine evaluation of
             the monoclonal component or by assay of serum free light chains.

          -  Age between 18 and 65 years at the time of signing the informed consent document.

          -  ECOG performance status &lt;2 (Karnofsky ≥ 60%)

          -  Negative HIV blood test

        Exclusion Criteria for registration (section 4.2):

          -  Participants must not have been treated with any prior systemic therapy for multiple
             myeloma. Treatment by localized radiotherapy is not an exclusion criterion if an
             interval of at least two weeks between the end of radiotherapy and initiation of
             protocol therapy entry in the study is observed. Similarly, the dose of
             corticosteroids received by the participant should not exceed the equivalent of 160 mg
             of dexamethasone over a two-week period before initiation of protocol therapy.

          -  Primary amyloidosis (AL) or myeloma complicated by amylosis.

          -  Participants may not be receiving any other study investigational agents.

          -  Participants with known brain metastases

          -  Poor tolerability or known allergy to any of the study drugs or compounds of similar
             chemical or biologic composition to study agents

          -  Platelet count &lt; 50,000/mm3 per µLwithin 21 days of initiation of protocol therapy.
             Transfusion within 7 days of screening is not allowed to meet platelet eligibility
             criteria.

          -  ANC &lt; 1,000 cells/mm3 within 21 days of initiation of protocol therapy. Growth factor
             within 7 days of screening is not allowed to meet ANC eligibility criteria.

          -  Hemoglobin &lt; 8.0 g/dL within 21 days of initiation of protocol therapy. Transfusion
             may be used to meet hemoglobin eligibility criteria.

          -  Hepatic impairment, defined a bilirubin &gt; 1.5 x institutional upper limit of normal
             (ULN) &gt; 2 mg/dL (Patients with benign hyperbilirubinemia (e.g., Gilbert's syndrome)
             are eligible) and or AST (SGOT), or ALT (SGPT), or alkaline phosphatase &gt; 2 x ULN

          -  Renal insufficiency, defined as serum creatinine &gt; 2.5 mg/dl and/or creatinine
             clearance &lt; &lt;40 60 ml/min (actual or calculated). The Cockgroft-Gault formula should
             be used for calculating creatinine clearance values, and may be located in Section 4.2

          -  Respiratory compromise, defined as ventilation tests and with DLCO &lt; 50%

          -  Participant must not demonstrate with clinical signs of heart or coronary failure, or
             evidence of LVEF &lt; 40%. Participant must not have with myocardial infarction within 6
             months prior to enrollment or have New York Heart Association (NYHA Appendix VII)
             Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular
             arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction
             system abnormalities. Prior to study entry, any ECG abnormality at screening has to be
             documented by the investigator as not medically relevant.

          -  Intercurrent illness including, but not limited to ongoing or active severe infection,
             known (active or not) infection with hepatitis B or C virus, poorly controlled
             diabetes, severe uncontrolled psychiatric disorder or psychiatric illness/social
             situations that would limit compliance with study requirements.

          -  Participant with previous history of another malignant condition, except for basal
             cell carcinoma and stage I cervical cancer

          -  Female participant who is pregnant or breast-feeding

          -  Inability to comply with an anti-thrombotic treatment regimen

          -  Peripheral neuropathy ≥ Grade 2 peripheral neuropathy on clinical examination within
             21 days of initiation of protocol therapy

          -  Mental illness likely to interfere with participation in the study and Adults under
             juridical protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MICHEL ATTAL, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH du Pays D'Aix</name>
      <address>
        <city>Aix-en-provence</city>
        <zip>13 616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Sud Amiens</name>
      <address>
        <city>AMIENS cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>ANGERS cedex 01</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Argenteuil Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95 100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier H.Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la côte basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Blois</name>
      <address>
        <city>Blois</city>
        <zip>41016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33 300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital A.Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caen Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH René Dubos</name>
      <address>
        <city>Cergy-Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier William Morey</name>
      <address>
        <city>Chalon-sur-saone</city>
        <zip>71 321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart cedex</city>
        <zip>92 141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'instruction des armées Percy</name>
      <address>
        <city>Clamart cedex</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pole Santé République</name>
      <address>
        <city>Clermont - Ferrand</city>
        <zip>63050</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Louis Pasteur - Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94 010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général - Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59 385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital A.Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier départemental - La Roche sur Yon cedex</name>
      <address>
        <city>La Roche sur Yon cedex</city>
        <zip>85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Chartres - Hôpital Louis Pasteur</name>
      <address>
        <city>Le Coudray</city>
        <zip>26630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Bodelio</name>
      <address>
        <city>Lorient</city>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital E Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux de Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44 202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet 1</name>
      <address>
        <city>NICE cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalo-Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cédex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>PARIS cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St-Antoine</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital du Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon sud</name>
      <address>
        <city>Pierre - Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la région d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital R.Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud Réunion</name>
      <address>
        <city>SAINT-PIERRE cedex</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>St Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Yves le Foll</name>
      <address>
        <city>St-Brieuc cedex 1</city>
        <zip>22 027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental - La réunion St Denis</name>
      <address>
        <city>St-denis</city>
        <zip>97 405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>St-priest-en-jarez</city>
        <zip>42 271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse, Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059 Cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valence</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Bretagne Atlantique Vannes et Auray</name>
      <address>
        <city>Vannes cedex</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif cedex</city>
        <zip>94 805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progression free survival prolongation</keyword>
  <keyword>Disease Progression</keyword>
  <keyword>Overall survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

